Otter Creek Advisors LLC bought a new position in shares of Plus Therapeutics, Inc. (NASDAQ:PSTV – Get Rating) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 83,901 shares of the company’s stock, valued at approximately $84,000. Otter Creek Advisors LLC owned about 0.38% of Plus Therapeutics at the end of the most recent quarter.
Analyst Upgrades and Downgrades
Several analysts have weighed in on PSTV shares. Maxim Group dropped their target price on shares of Plus Therapeutics to $2.00 in a research report on Thursday, May 26th. HC Wainwright dropped their price objective on shares of Plus Therapeutics from $7.00 to $3.50 and set a “buy” rating on the stock in a report on Friday, July 22nd.
Plus Therapeutics Stock Performance
Shares of PSTV stock traded down $0.02 during trading hours on Friday, hitting $0.48. The company’s stock had a trading volume of 274,877 shares, compared to its average volume of 63,725. The company has a 50 day moving average of $0.55 and a 200 day moving average of $0.76. The company has a quick ratio of 2.71, a current ratio of 2.71 and a debt-to-equity ratio of 0.46. Plus Therapeutics, Inc. has a 12-month low of $0.39 and a 12-month high of $2.32.
Plus Therapeutics Company Profile
Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
- Get a free copy of the StockNews.com research report on Plus Therapeutics (PSTV)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Receive News & Ratings for Plus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Plus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.